Antioxidant enzymatic protein levels may predict cardiovascular disease risk in patients with PA

Researchers from the Cleveland Clinic found that low levels of antioxidant enzymatic proteins may indicate increased inflammation, oxidation stress and a more severe risk of cardiovascular disease risk in patients with psoriasis and psoriatic arthritis, according to a recent presentation at the American College of Rheumatology meeting.

“These observations help to better define oxidative stress in psoriatic disease patients and predict [cardiovascular] disease risk for this at-risk patient population,” M. Elaine Husni, MD, MPH, a rheumatologist and director of the Arthritis & Musculoskeletal Treatment Center at the Cleveland Clinic, told Healio.com. “These measures can be more precise and independent of systemic inflammatory disease burden in patients with psoriasis and psoriatic arthritis.”

Husni and colleagues measured baseline serum levels of paraoxonase and arylesterase in 289 patients with psoriasis and psoriatic arthritis (PA) included in the Cardiometabolic Outcome Measures in Psoriatic Arthritis Study (COMPASS) study. They used the Framingham risk score to subdivide the patients into low-, intermediate- and high-risk groups, and analysis of variance was used to compare mean serum levels across the groups.

The researchers found that for patients with PA, there was a statistically significant inverse relationship between serum paraoxonase and arylesterase levels and risk of coronary heart disease.

Baseline levels of serum paraoxonase and arylesterase carried a significant Framingham risk score of 20% or higher. However, Husni and colleagues found there was no significant link between serum paraoxonase and arylesterase levels for patients with psoriasis. — by Jeff Craven

Reference:

Husni ME. Paper #1591. Presented at: American College of Rheumatology Annual Meeting. Nov. 14-19, 2014; Boston.

Disclosure: See the study for a full list of all authors’ relevant financial disclosures.